Table 1.

Summary of the METEOR trial results with subgroup analyses

Subgroups (no. of pts) (cabozantinib/everolimus)	Overall survival: median HR (95%CI)	Progression-free survival: median HR (95%CI)
Cabozantinib (330)	21.4 months (18.4–NR)	7.4 months (5.6–9.1)
Everolimus (328)	16.5 months(14.7–18.8)	3.8 months (3.7–5.1)
	HR = 0·66 [0·53–0·83]	HR = 0·58 [0·45–0·75]
MSKCC risk groups:
Favorable (150/150)	0.66 (0.46–0.96)	0.51 (0.38–0.69)
Intermediate (139/135)	0.67 (0.48–0.94)	0.47 (0.35–0.65)
Poor (41/43)	0.65 (0.39–1.07)	0.70 (0.42–1.16)
IMDC risk groups:
Favorable (66/62)	0.70 (0.34–1.41)	0.47 (0.30–0.76)
Intermediate (210/214)	0.65 (0.49–0.85)	0.48 (0.37–0.62)
Poor (54/52)	0.74 (0.48–1.15)	0.67 (0.48–1.04)
Prior nephrectomy:
No (47/49)	0.75(0.44–1.27)	0.51(0.30–0.86)
Yes(283/279)	0.66(0.52–0.84)	0.51(0.41–0.64)
Bone mets
No (253/263)	0.71(0.55–0.91)	0.57(045–0.71)
Yes (77/65)	0.54(0.34–0.84)	0.33(0.21–0.51)
Number of previous VEGFR TKI:
1 (235/229)	0.65(0.50–0.85)	0.52(0.41–0.66)
2 or more (95/99)	0.73(0.48–1.10)	0.51(0.35–0.74)
Duration of first VEGFR:
6 months or less (88/102)	0.69(0.47–1.01)	0.62(0.44–0.89)
>6 months (242/224)	0.69(0.52–0.90)	0.48(0.38–0.62)